Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE

被引：0
|
作者：
Arnold, D. L. [1 ,2 ]
Fox, R. J. [3 ]
Gold, R. [4 ]
Havrdova, E. [5 ]
Kappos, L. [6 ]
Yousry, T. [7 ]
MacManus, D. [7 ]
Zhang, R. [8 ]
Yang, M. [8 ]
Rana, J. [8 ]
机构：
[1] McGill Univ, NeuroRx Res, Montreal, PQ, Canada
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[5] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic
[6] Univ Basel Hosp, Basel Neurol, CH-4031 Basel, Switzerland
[7] UCL, Inst Neurol, Queen Sq Multiple Sclerosis Ctr, NMR Res Unit, London, England
[8] Biogen Inc, Cambridge, MA 02142 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P566
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [21] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [22] Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
    Lilyana Amezcua
    Yang Mao-Draayer
    Wendy S. Vargas
    Rebecca Farber
    Sara Schaefer
    Filipe Branco
    Sarah M. England
    Nicholas Belviso
    James B. Lewin
    Jason P. Mendoza
    Sai L. Shankar
    Neurology and Therapy, 2023, 12 : 883 - 897
  • [23] Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
    Amezcua, Lilyana
    Mao-Draayer, Yang S.
    Vargas, Wendy
    Farber, Rebecca
    Schaefer, Sara
    Branco, Filipe M.
    England, Sarah
    Belviso, Nicholas B.
    Lewin, James P.
    Mendoza, Jason L.
    Shankar, Sai
    ENDORSE Study Investigators
    NEUROLOGY AND THERAPY, 2023, 12 (03) : 883 - 897
  • [24] Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM
    Havrdova, E.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. T.
    Zhang, A.
    Kurukulasuriya, N. C.
    Sheikh, S. I.
    Viglietta, V.
    Giovannoni, G.
    JOURNAL OF NEUROLOGY, 2014, 261 : S304 - S305
  • [25] Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM
    Havrdova, E.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. T.
    Zhang, A.
    Kurukulasuriya, N. C.
    Sheikh, S. I.
    Viglietta, V.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 459 - 459
  • [26] Effect of aspirin on flushing in relapsing-remitting multiple sclerosis patients receiving delayed-release dimethyl fumarate
    Rog, D.
    Cader, S.
    Harrower, T.
    McGuigan, C.
    Young, C.
    Potts, J.
    Hanna, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 656 - 657
  • [27] Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
    Fox R.J.
    Gold R.
    Phillips J.T.
    Okwuokenye M.
    Zhang A.
    Marantz J.L.
    Neurology and Therapy, 2017, 6 (2) : 175 - 187
  • [28] Efficacy and safety of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis patients with cardiovascular disease: integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Havrdova, E.
    Fox, R. J.
    Gold, R.
    Li, J.
    Zhang, A.
    Potts, J.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 551 - 552
  • [29] Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
    Havrdova, E.
    Giovannoni, G.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. Theodore
    Okwuokenye, M.
    Marantz, J. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (05) : 726 - 733
  • [30] Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
    Kurukulasuriya, N. C.
    Gold, R.
    Phillips, J. T.
    Bar-Or, A.
    Hutchinson, M.
    Kappos, L.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 116 - 117
12345